Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2 Thoracic 1 Other hematologic neoplasm 1 Endocrine 1 CNS 1 Breast 1

Conditions

Neurofibromatosis 1 1

Interventions

Temozolomide 165 Magnetic Resonance Spectroscopy 130 Radiotherapy 95 Specimen Handling 80 Radiosurgery 60 Cyclophosphamide 55 pembrolizumab 51 Bevacizumab 51 Nivolumab 48 Radiation 47 Carboplatin 34 Biopsy 33 Irinotecan 29 Lomustine 25 Etoposide 25 Vincristine 23 Topotecan 23 Ipilimumab 23 dinutuximab 21 Cisplatin 21 Blood Specimen Collection 21 fludarabine 19 Radiotherapy, Intensity-Modulated 19 X-Rays 18 Surgical Procedures, Operative 18 abemaciclib 16 Mental Status and Dementia Tests 16 Granulocyte-Macrophage Colony-Stimulating Factor 16 Pemetrexed 15 atezolizumab 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Dosage Forms × CNS × 1 year × Clear all

NCT05309668 2025-12-18

SPRINKLE

AstraZeneca

Phase 1/2 Active not recruiting

36 enrolled 37 charts

Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡